Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES

被引:48
|
作者
Nardese, V
Longhi, R
Polo, S
Sironi, F
Arcelloni, C
Paroni, R
DeSantis, C
Sarmientos, P
Rizzi, M
Bolognesi, M
Pavone, V
Lusso, P [1 ]
机构
[1] San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy
[2] CNR, IRBM, I-20131 Milan, Italy
[3] San Raffaele Sci Inst, Lab Separat Tech, I-20132 Milan, Italy
[4] PRIMM Srl, I-20132 Milan, Italy
[5] Univ Eastern Piemonte, DISCAFF Dept, I-28100 Novara, Italy
[6] Univ Genoa, Adv Biotechnol Ctr, IST, I-16132 Genoa, Italy
[7] Univ Genoa, Dept Phys, INFM, I-16132 Genoa, Italy
[8] Univ Naples Federico II, Dept Chem, I-80126 Naples, Italy
[9] Univ Bologna, Dept Clin & Expt Med, I-40138 Bologna, Italy
关键词
D O I
10.1038/89653
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Certain chemokines act as natural antagonists of human immunodeficiency virus (HIV) by blocking key viral coreceptors, such as CCR5 and CXCR4, on the surface of susceptible cells. Elucidating the structural determinants of the receptor-binding and HIV-inhibitory functions of these chemokines is essential for the rational design of derivative molecules of therapeutic value. Here, we identify the structural determinants of CCR5 recognition and antiviral activity of the CC chemokine RANTES, showing that critical residues form a solvent-exposed hydrophobic patch on the surface of the molecule. Moreover, we demonstrate that the biological function is critically dependent on dimerization, resulting in the exposure of a large (similar to 180 Angstrom (2)), continuous hydrophobic surface. Relevant to the development of novel therapeutic approaches, we designed a retroinverted RANTES peptide mimetic that maintained both HIV- and chemotaxis-antagonistic functions.
引用
收藏
页码:611 / 615
页数:5
相关论文
共 50 条
  • [1] Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES
    Vanessa Nardese
    Renato Longhi
    Simona Polo
    Francesca Sironi
    Cinzia Arcelloni
    Rita Paroni
    Claudio DeSantis
    Paolo Sarmientos
    Menico Rizzi
    Martino Bolognesi
    Vincenzo Pavone
    Paolo Lusso
    [J]. Nature Structural Biology, 2001, 8 : 611 - 615
  • [2] CCR5 structural plasticity shapes HIV-1 phenotypic properties
    Colin, Philippe
    Zhou, Zhicheng
    Staropoli, Isabelle
    Garcia-Perez, Javier
    Gasser, Romain
    Armani-Tourret, Marie
    Benureau, Yann
    Gonzalez, Nuria
    Jin, Jun
    Connell, Bridgette J.
    Raymond, Stephanie
    Delobel, Pierre
    Izopet, Jacques
    Lortat-Jacob, Hugues
    Alcami, Jose
    Arenzana-Seisdedos, Fernando
    Brelot, Anne
    Lagane, Bernard
    [J]. PLOS PATHOGENS, 2018, 14 (12)
  • [3] CCR5 HIV-1 vertical transmission
    Shearer, WT
    Kalish, LA
    Zimmerman, PA
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 180 - 181
  • [4] CCR5, RANTES and SDF-1 polymorphisms and mother-to-child HIV-1 transmission
    Katz, D. A.
    John-Stewart, G. C.
    Richardson, B. A.
    Majiwa, M.
    Mabuka, J. M.
    Lohman-Payne, B.
    Farquhar, C.
    [J]. INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2010, 37 (04) : 301 - 305
  • [5] CCR5 inhibitors in HIV-1 therapy
    Dorr, Patrick
    Perros, Manos
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
  • [6] Recognition of RANTES by extracellular parts of the CCR5 receptor
    Duma, Luminita
    Haeussinger, Daniel
    Rogowski, Marco
    Lusso, Paolo
    Grzesiek, Stephan
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2007, 365 (04) : 1063 - 1075
  • [7] Structural determinants of the interaction between Toxoplasma gondii cyclophilin and the HIV-1 co-receptor CCR5
    Yarovinsky, F
    Andersen, JF
    Khurana, S
    King, LR
    Aliberti, J
    Golding, H
    Sher, A
    [J]. FASEB JOURNAL, 2005, 19 (04): : A939 - A939
  • [8] Engineering of Lactobacillus jensenii To Secrete RANTES and a CCR5 Antagonist Analogue as Live HIV-1 Blockers
    Vangelista, Luca
    Secchi, Massimiliano
    Liu, Xiaowen
    Bachi, Angela
    Jia, Letong
    Xu, Qiang
    Lusso, Paolo
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) : 2994 - 3001
  • [9] Choosing CCR5 or Rev siRNA in HIV-1
    Arteaga, HJ
    Hinkula, J
    van Dijk-Härd, I
    Dilber, MS
    Wahren, B
    Christensson, B
    Mohamed, AJ
    Smith, CIE
    [J]. NATURE BIOTECHNOLOGY, 2003, 21 (03) : 230 - 231
  • [10] CCR5 monoclonal antibodies for HIV-1 therapy
    Olson, William C.
    Jacobson, Jeffrey M.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 104 - 111